Shots:

• Thermo Fisher acquires Mesa Biotech for $450M in cash. Mesa Biotech will receive an additional ~$100M in cash on the completion of milestones while the transaction is expected to be completed in Q1’21
• Mesa has developed & commercialized a PCR-based rapid POC testing platform for detecting infectious diseases. Messa’s technology inflates the availability of gold-standard nucleic acid PCR amplification to POC diagnostic
• Mesa’s Accula Flu A/Flu B- RSV- and Strep A tests received the US FDA’s 510 (k) clearance while its Accula has received FDA’s EUA for SARS-CoV-2 IVD testing and is now available for use in patient care settings- providing results within 30min

 ­ Ref: PRNewswire | Image: Mesa Biotech